Psychedelic News

  • PYSENCE_INGENU_FEATURE_2

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

2023-03-21T17:14:12+02:00March 21, 2023|Press Releases, Investor Information, Psychedelic News|

Psyence Australia Pty Ltd, has partnered with iNGENū Pty Ltd (iNGENū) to conduct Psyence’s previously announced clinical trial in palliative care. iNGENū is an Australian based, globally focused Contract Research Organization (CRO) with extensive experience working in the psychedelic pharmaceutical drug development and clinical research industry.

  • GOODMIND_FEATURE

GOODMIND Available For Sale In The United Kingdom And Europe – Exclusive Distribution Agreement Concluded With This Works.

2022-11-29T19:40:20+02:00November 29, 2022|Investor Information, Psychedelic News, Press Releases|

Psyence is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), entered into an exclusive distribution agreement with This Works Products Limited (“This Works”) for the distribution and sale of the joint venture’s functional mushroom brand, GOODMINDTM, in the United Kingdom and Europe.

Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain

2021-12-02T15:19:55+02:00December 2, 2021|Investor Information, Psychedelic News, Press Releases|

Psyence is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.

  • Global Wellness Summit - Psilocybin - Boston

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit

2021-11-27T05:48:16+02:00November 26, 2021|Press Releases, Investor Information, Psychedelic News|

Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing. 

Go to Top